Azithromycin

Generic Name: Azithromycin

Brand Names: Azasite, Zithromax, Zmax

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₇₂N_₂O_₁₂

CAS Number: 83905-01-5

Unique Ingredient Identifier: J2KLZ20U1M

Background: Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...

Indication: Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis

Associated Therapies: -

Clinical Trials

the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris

Phase 2

Conditions: Acne

Interventions: Drug: Azithromycin
Drug: Doxycycline

First Posted Date: 2007-01-09

Last Posted Date: 2008-01-29

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT00419848

Locations: 🇮🇷
Shaheed Beheshti Medical University, Skin research center, Tehran, Iran, Islamic Republic of

Bronchiectasis and Long Term Azithromycin Treatment

Phase 3

Completed

Conditions: Bronchiectasis
Inflammation

Interventions: Other: Placebo
Drug: Azithromycin

First Posted Date: 2006-12-22

Last Posted Date: 2020-05-28

Lead Sponsor: W.G.Boersma

Target Recruit Count: 72

Registration Number: NCT00415350

Locations: 🇳🇱
Viecuri MC, Venlo, Netherlands
🇳🇱
U.L.C. Dekkerswald, Groesbeek, Netherlands
🇳🇱
Tergooi Ziekenhuizen, Hilversum, Netherlands

and more 13 locations

Chloroquine Alone or in Combination for Malaria in Children in Malawi

Phase 3

Completed

Conditions: Plasmodium Falciparum Infection

Interventions: Drug: Atovaquone-proguanil
Drug: Chloroquine
Drug: Artesunate
Drug: Azithromycin

First Posted Date: 2006-09-25

Last Posted Date: 2014-08-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 640

Registration Number: NCT00379821

Locations: 🇲🇼
Blantyre Malaria Project - Ndirande Health Centre, Blantyre, Malawi

Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

Phase 3

Completed

Conditions: Otitis Media

First Posted Date: 2006-08-03

Last Posted Date: 2011-05-17

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT00360100

Locations: 🇵🇦
Pfizer Investigational Site, Ciudad de Panama, Panama

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

Phase 3

Completed

Conditions: Urethritis

Interventions: Drug: Azithromycin
Drug: Doxycycline

First Posted Date: 2006-07-31

Last Posted Date: 2018-08-15

Lead Sponsor: University of Washington

Target Recruit Count: 606

Registration Number: NCT00358462

Locations: 🇺🇸
Public Health -- Seattle & King County Sexually Transmitted Diseases Clinic located at Harborview Medical Center, Seattle, Washington, United States

Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers

Phase 1

Completed

Conditions: Eye Infections, Bacterial

First Posted Date: 2006-07-26

Last Posted Date: 2006-07-26

Lead Sponsor: Laboratoires Thea

Registration Number: NCT00356850

Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma

Phase 3

Completed

Conditions: Trachoma

First Posted Date: 2006-07-26

Last Posted Date: 2006-07-26

Lead Sponsor: Laboratoires Thea

Registration Number: NCT00356720

Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers

Phase 1

Completed

Conditions: Eye Infections, Bacterial

First Posted Date: 2006-07-26

Last Posted Date: 2006-07-26

Lead Sponsor: Laboratoires Thea

Registration Number: NCT00356772

Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia

Phase 4

Completed

Conditions: Trichiasis

Interventions: Drug: topical tetracycline
Drug: azithromycin

First Posted Date: 2006-07-04

Last Posted Date: 2017-08-07

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1452

Registration Number: NCT00347776

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

Phase 2

Completed

Conditions: Urethritis

Interventions: Other: Placebo
Drug: Tinidazole
Drug: Doxycycline
Drug: Azithromycin

First Posted Date: 2006-05-08

Last Posted Date: 2019-03-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 305

Registration Number: NCT00322465

Locations: 🇺🇸
Delgado Personal Health Center, New Orleans, Louisiana, United States
🇺🇸
University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸
University of North Carolina School of Medicine - Center for Infectious Diseases, Chapel Hill, North Carolina, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy